Topical corticosteroids remain a cornerstone of atopic dermatitis care, but steroid phobia and a growing roster of nonsteroidal agents are reshaping how clinicians use them. On this episode…
Exosomes in dermatology are moving closer to a regulatory pathway, and a new remibrutinib label update is changing how clinicians approach symptomatic dermographism. Todd Schlesinger, MD, shares the…
NEW YORK (Reuters Health) – In children with severe atopic dermatitis prone to infections, a regimen of dilute sodium hypochlorite baths and intermittent intranasal mupirocin reduces disease severity,…
NEW YORK (Reuters Health) – Results of a prospective, 14-year study indicate that women with psoriasis are at increased risk of incident diabetes and hypertension, verifying previous findings…
NEW YORK (Reuters Health) – Certain women may be at risk of developing systemic lupus erythematosus (SLE) when they start taking combined oral contraceptives, according to investigators at…
NEW YORK (Reuters Health) – The results of a placebo-controlled trial suggest that controlled-release oxycodone is an effective treatment for acute pain due to herpes zoster, whereas gabapentin…
Howard Krein , MD, PhD, Assistant Professor of Otolaryngology, Head and Neck Surgery at Jefferson University, discusses the history of botulinum toxin A, its clinical uses and how…
Howard Krein, MD, PhD, Assistant Professor of Otolaryngology – Head and Neck Surgery at Jefferson College Medical School, discusses the most popular cosmetic fillers, restylane, perlane and juvederm,…
Mark B. Lewin, MD, Chief, Cardiology, Co-Director Heart Center, Seattle Children’s Hospital and Regional Medical Center, describes the evolution of telemedicine and its uses for consultations and sending…
Howard Krein, MD, PhD, Assistant professor of Otolaryngology and Head and Neck Surgery at Jefferson College Medical School, discusses the most popular cosmetic fillers, restylane, perlane and juvederm,…
NEW YORK (Reuters Health) – In patients with rheumatoid arthritis, anti-tumor necrosis factor (TNF) treatment with adalimumab and infliximab is associated with a small increased risk of herpes…
NEW YORK (Reuters Health) – In patients with diffuse cutaneous systemic sclerosis (dcSSc), treatment with rituximab depletes B cells in the peripheral circulation and in skin, with few…
